The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

actavis.com

Founded Year

1984

Stage

Acquired Unit | Acquired

Valuation

$0000 

About Actavis Generics

Actavis Generics is a global pharmaceutical company focused on developing, manufacturing, and commercializing branded pharmaceuticals, generic and over-the-counter medicines, and biologic products. Actavis Generics was previously a subsidiary of Allergan plc.

Actavis Generics Headquarter Location

Clonshaugh Business and Technology Park Coolock

Dublin, D17 E400,

Ireland

862-261-7000

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Actavis Generics Patents

Actavis Generics has filed 7 patents.

patents chart

Application Date

Grant Date

Title

Related Topics

Status

1/5/2016

10/22/2019

Muscarinic antagonists, Amines, Dosage forms, Piperidines, Drug delivery devices

Grant

Application Date

1/5/2016

Grant Date

10/22/2019

Title

Related Topics

Muscarinic antagonists, Amines, Dosage forms, Piperidines, Drug delivery devices

Status

Grant

Latest Actavis Generics News

INVESTOR ALERT Holzer & Holzer Announces a Class Action Lawsuit Filed on Behalf of Investors in Teva

Aug 28, 2017

INVESTOR ALERT: Khang & Khang LLP Announces a Securities Class Action Lawsuit against Amyris, Inc. and Reminds Investors with Losses to Contact the Firm Specifically, the Complaint alleges Teva failed to disclose the poor performance of its U.S. generics business and the subsequent goodwill impairment charge stemming from the Company’s purchase of Actavis Generics. On August 3, 2017, Teva announced a $6.1 million goodwill impairment charge in the second quarter of 2016. The price of Teva common stock has declined following the report. If you purchased Teva shares between November 15, 2016 and August 2, 2017 and suffered losses on that investment, you are encouraged to visit the firm’s website at www.holzerlaw.com to receive additional information about your legal rights. You can also contact Corey D. Holzer, Esq. at cholzer@holzerlaw.com or Alexandria P. Rankin, Esq. at arankin@holzerlaw.com , or call the firm by toll-free telephone at (888) 508-6832 for more information. The case is pending in the United States District Court for the Eastern District of Pennsylvania and the deadline to move for appointment as lead plaintiff is October 23, 2017. Holzer & Holzer, LLC is an Atlanta, Georgia law firm that dedicates its practice to vigorous representation of shareholders and investors in litigation nationwide, including shareholder class action and derivative litigation. More information about the firm is available through its website, www.holzerlaw.com and upon request from the firm. Holzer & Holzer, LLC has paid for the dissemination of this promotional communication, and Corey D. Holzer is the attorney responsible for its content. View source version on businesswire.com: http://www.businesswire.com/news/home/20170828005729/en/ Holzer & Holzer, LLC

  • When was Actavis Generics founded?

    Actavis Generics was founded in 1984.

  • Where is Actavis Generics's headquarters?

    Actavis Generics's headquarters is located at Clonshaugh Business and Technology Park, Dublin.

  • What is Actavis Generics's latest funding round?

    Actavis Generics's latest funding round is Acquired Unit.

  • Who are the investors of Actavis Generics?

    Investors of Actavis Generics include Teva Pharmaceuticals.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.